We are live on ! Find out more
CTOR

Citius Oncology
CTOR

24 hedge funds and large institutions have $54.1M invested in Citius Oncology in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 2 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

900% more first-time investments, than exits

New positions opened: 10 | Existing positions closed: 1

150% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 2

60% more funds holding

Funds holding: 15 → 24 (+9)

58% more capital invested

Capital invested by funds: $34.3M → $54.1M (+$19.8M)

Holders
24
Holders Change
+9
Holders Change %
+60%
% of All Funds
0.38%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
10
Increased
5
Reduced
2
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WAM
Wolverine Asset Management
Illinois
+$5.97M
2
PC
Periscope Capital
Ontario, Canada
+$3.33M
3
KIM
Karpus Investment Management
New York
+$3.28M
4
RCM
Radcliffe Capital Management
Pennsylvania
+$2.53M
5
SCM
Shaolin Capital Management
Florida
+$2.06M

Top Sellers

Rank Fund Capital Flow
1
MP
Mangrove Partners
Connecticut
-$1.52M
2
CH
CVI Holdings
Delaware
-$76.4K
3
AA
AQR Arbitrage
Connecticut
-$36K

CTOR Hedge Fund Activity: Q1 2023 in Review

24 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Citius Oncology (CTOR) for Q1 2023, worth a combined $54.1M — up 58% from $34.3M a quarter earlier.

Buyers outnumbered sellers: 10 funds opened new CTOR positions and 1 closed out — a net gain of 9 holders — while 5 added to existing stakes and 2 trimmed.

The largest buyer was Wolverine Asset Management, opening a new position worth an estimated $5.97M. The largest seller was Mangrove Partners, exiting entirely with an estimated $1.52M sold.

  • 24 institutional investors held Citius Oncology (CTOR) as of Q1 2023, up from 15 in Q4 2022.
  • Funds reported $54.1M of Citius Oncology stock for Q1 2023, up 58% quarter-over-quarter.
  • 10 funds opened new Citius Oncology positions in Q1 2023 and 1 closed out, a net change of +9 holders.
  • The largest Citius Oncology buyer in Q1 2023 was Wolverine Asset Management, an estimated $5.97M added.
  • The largest Citius Oncology seller in Q1 2023 was Mangrove Partners, an estimated $1.52M sold.

Based on aggregated 13F filings for Q1 2023.